|Table of Contents|

Study of miR197-p53 pathway in triple negative and hormone receptor dependent breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 04
Page:
553-555
Research Field:
Publishing date:

Info

Title:
Study of miR197-p53 pathway in triple negative and hormone receptor dependent breast cancer
Author(s):
Liu Chunsheng; Dong Chao; Du Jiang; Ma Binlin
Department of Breast and Neck Surgery,Affiliated Tumour Hospital,Xinjiang Medical University,Xinjiang Urumqi 830011,China.
Keywords:
triple negative breast cancer; apoptosis; miR197
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2017.04.013
Abstract:
Objective:To investigate the expression and prognosis mechanism of miR197 in invasive breast cancer.Methods:Collecting serum of healthy women（n=10),patients with hormone receptor dependent（ER or/and PR positive,Her-2 negative) breast cancer（n=40),triple patients with negative breast cancer（n=40) tumor samples.Detecting the miR197 in serum samples of three groups through the Real-time PCR.Detecting the expression of apoptosis protein in two groups of patients with breast cancer by Western Blotting.Results:The low expression of miR197 in patients with 42.5% patients with triple negative breast cancer（31/40).Hormone receptor dependent breast cancer（17/40) and 20.0% normal women（2/10),P＜0.05.miR197 expression in breast cancer patients with low expression of p53 was higher,and it was more likely to occur apoptosis.Conclusion:The expression of miR197 in breast cancer cells is low,and it is associated with poor prognosis.

References:

［1］Gu G,Gelsomino L,Covington KR,et al.Targeting thyroid hormone receptor beta in triple-negative breast cancer［J］.Breast Cancer Res Treat,2015,150(3):535-545.
[2]Gelmon K,Dent R,Mackey JR,et al.Targeting triple-negative breast cancer:Optimising therapeutic outcomes［J］.Ann Oncol,2012,23(9):2223-2234.
[3]Weigelt B,Reis-Filho JS.Histological and molecular types of breast cancer:Is there a unifying taxonomy［J］.Nat Rev Clin Oncol,2009,6(12):718-730.
[4]Xiong HL,Zhou SW,Sun AH,et al.MicroRNA-197 reverses the drug resistance of fluorouracil-induced SGC7901 cells by targeting mitogen-activated protein kinase 1［J］.Mol Med Rep,2015,12(4):5019-5025.
[5]Li Suoni，Yao Yu，Nan Kejun.Progression of triple-negative breast cancer treatment［J］.Modern Oncology,2014,22(1):197-200.
[6]Fitzgibbons PL,Page DL,Weaver D,et al.Prognostic factors in breast cancer［J］.Arch Pathol Lab Med,2000,124(7):966-978.
[7]Wang F,Zheng Z,Guo J,et al.Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor ［J］.Gynecol Oncol,2010,119(3):586-593.
[8]Tian LQ,Liu EQ,Zhu XD,et al.MicroRNA-197 inhibits cell proliferation by targeting GAB2 in glioblastoma［J］.Mol Med Rep,2016,13(5):4279-4288.
[9]Elledge RM,Green S,Howes L,et al.Bcl-2,p53,and response to tamoxifen in estrogen receptor-positive metastatic breast cancer:A Southwest Oncology Group Study［J］.J Clin Oncol,1997,15(5):1916-1922.
[10]Kaik,Nishimurar,Matsudam,et al.p53 overexpression is a significant factor in predicting resistance to 3rd generation aromatase inhibitors（AIs) in hormone sensitive recurrent or advanced breast cancer［J］.J Clinical,2005,23(16):715.
[11]Fiannaca A,La Rosa M,La Paglia L，et al.Analysis of miRNA expression profiles in breast cancer using biclustering［J］.BMC Bioinformatics,2015,16(Suppl 4):7065-7070.

Memo

Memo:
新疆医科大学科研创新基金（编号：XYDCX201565）
Last Update: 2016-12-29